enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
Go back to enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve| (NASDAQ: NVNO) | Delayed: 10.60 -0.03 (0.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.63 | 52 Week High | $ | |||
| Open | $10.60 | 52 Week Low | $ | |||
| Day High | $10.60 | P/E | N/A | |||
| Day Low | $10.60 | EPS | $ | |||
| Volume | 2,338 | |||||
